BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25163630)

  • 1. Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population.
    Salazar-González R; Gómez R; Romano-Moreno S; Medellín-Garibay S; Núñez-Ruíz A; Magaña-Aquino M; Milán-Segovia RC; Portales-Pérez DP
    Mol Biol Rep; 2014 Dec; 41(12):7833-43. PubMed ID: 25163630
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Mthiyane T; Millard J; Adamson J; Balakrishna Y; Connolly C; Owen A; Rustomjee R; Dheda K; McIlleron H; Pym AS
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
    Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes.
    Hein DW; Doll MA
    Pharmacogenomics; 2012 Jan; 13(1):31-41. PubMed ID: 22092036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
    Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
    Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs.
    Guaoua S; Ratbi I; El Bouazzi O; Hammi S; Tebaa A; Bourkadi JE; Bencheikh RS; Sefiani A
    Genet Test Mol Biomarkers; 2016 Nov; 20(11):680-684. PubMed ID: 27541622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
    Jung JA; Kim TE; Lee H; Jeong BH; Park HY; Jeon K; Kwon OJ; Ko JW; Choi R; Woo HI; Koh WJ; Lee SY
    Drug Des Devel Ther; 2015; 9():5433-8. PubMed ID: 26491254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.
    Kita T; Tanigawara Y; Chikazawa S; Hatanaka H; Sakaeda T; Komada F; Iwakawa S; Okumura K
    Biol Pharm Bull; 2001 May; 24(5):544-9. PubMed ID: 11379777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.
    Singh N; Dubey S; Chinnaraj S; Golani A; Maitra A
    Mol Diagn Ther; 2009; 13(1):49-58. PubMed ID: 19351215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
    Yuliwulandari R; Prayuni K; Susilowati RW; M Sofro AS; Tokunaga K; Shin JG
    Pharmacogenomics; 2019 Dec; 20(18):1303-1311. PubMed ID: 31699005
    [No Abstract]   [Full Text] [Related]  

  • 12. Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.
    Cho YS; Jang TW; Kim HJ; Oh JY; Lee HK; Park HK; Ghim JL; Long NP; Park Y; Choi YK; Phuong NTT; Shin JG;
    J Clin Pharmacol; 2021 Dec; 61(12):1567-1578. PubMed ID: 34157153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
    Jing W; Zong Z; Tang B; Wang J; Zhang T; Wen S; Xue Y; Chu N; Zhao W; Huang H
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Genetic Variation of
    Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population.
    Djordjevic N; Carrillo JA; Ueda N; Gervasini G; Fukasawa T; Suda A; Jankovic S; Aklillu E
    J Clin Pharmacol; 2011 Jul; 51(7):994-1003. PubMed ID: 20801937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
    Chan SL; Chua APG; Aminkeng F; Chee CBE; Jin S; Loh M; Gan SH; Wang YT; Brunham LR
    PLoS One; 2017; 12(10):e0186200. PubMed ID: 29036176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients.
    Fukino K; Sasaki Y; Hirai S; Nakamura T; Hashimoto M; Yamagishi F; Ueno K
    J Toxicol Sci; 2008 May; 33(2):187-95. PubMed ID: 18544910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Acetyltransferase 2 (NAT2) polymorphism as a risk modifier of susceptibility to pediatric acute lymphoblastic leukemia.
    Kamel AM; Ebid GT; Moussa HS
    Tumour Biol; 2015 Aug; 36(8):6341-8. PubMed ID: 25804798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis.
    Huerta-García AP; Medellín-Garibay SE; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
    Int J Clin Pharm; 2020 Aug; 42(4):1217-1226. PubMed ID: 32638292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.
    Kubota R; Ohno M; Hasunuma T; Iijima H; Azuma J
    Eur J Clin Pharmacol; 2007 Oct; 63(10):927-33. PubMed ID: 17665185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.